Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and m...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841551937656324096 |
|---|---|
| author | Alberto Esteban-Fernández Alberto Esteban-Fernández Alejandro Recio-Mayoral Raquel López-Vilella Raquel López-Vilella Gregorio de Lara Moisés Barrantes-Castillo Inés Gómez-Otero Inés Gómez-Otero Julio Nuñez-Villota Julio Nuñez-Villota Julio Nuñez-Villota Julio Nuñez-Villota Carolina Robles-Gamboa José López-Aguilera Ángel Iniesta-Manjavacas Paula Fluviá Francisco Pastor-Pérez Laia Belarte-Tornero Gonzalo Alonso-Salinas Pablo Díez-Villanueva |
| author_facet | Alberto Esteban-Fernández Alberto Esteban-Fernández Alejandro Recio-Mayoral Raquel López-Vilella Raquel López-Vilella Gregorio de Lara Moisés Barrantes-Castillo Inés Gómez-Otero Inés Gómez-Otero Julio Nuñez-Villota Julio Nuñez-Villota Julio Nuñez-Villota Julio Nuñez-Villota Carolina Robles-Gamboa José López-Aguilera Ángel Iniesta-Manjavacas Paula Fluviá Francisco Pastor-Pérez Laia Belarte-Tornero Gonzalo Alonso-Salinas Pablo Díez-Villanueva |
| author_sort | Alberto Esteban-Fernández |
| collection | DOAJ |
| description | IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and methodsThis cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) years. Patients in VERISEC were older and had more comorbidities (diabetes, advanced chronic kidney disease) compared to VICTORIA, with 20% having an estimated glomerular filtration rate below 30 ml/min. They also had higher natriuretic peptide levels [NT-proBNP: 3551 (IQR: 1,675.9, 7,054.0)] pg/ml. Most patients (79.8%) started vericiguat after HF decompensation within the previous three months, with high use of loop diuretics (with an average dose of 65 mg/day) and implanted devices (50%). Sixty percent of patients were on quadruple therapy, with a higher use of sodium-glucose co-transporter 2 inhibitors compared to the VICTORIA trial. Despite the more severe disease in the VERISEC cohort, the implementation of guideline-directed medical therapy was greater than in VICTORIA, although vericiguat was initiated at lower blood pressure levels.ConclusionsPatients in the VERISEC registry had more severe illness and higher comorbidities compared to those in the VICTORIA, despite receiving optimised treatments. Further research is needed to identify which patients may benefit the most from vericiguat treatment. |
| format | Article |
| id | doaj-art-bae083b39bcc4e5595c0362e97e3619b |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-bae083b39bcc4e5595c0362e97e3619b2025-01-09T14:21:00ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-01-011110.3389/fcvm.2024.15044271504427Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trialAlberto Esteban-Fernández0Alberto Esteban-Fernández1Alejandro Recio-Mayoral2Raquel López-Vilella3Raquel López-Vilella4Gregorio de Lara5Moisés Barrantes-Castillo6Inés Gómez-Otero7Inés Gómez-Otero8Julio Nuñez-Villota9Julio Nuñez-Villota10Julio Nuñez-Villota11Julio Nuñez-Villota12Carolina Robles-Gamboa13José López-Aguilera14Ángel Iniesta-Manjavacas15Paula Fluviá16Francisco Pastor-Pérez17Laia Belarte-Tornero18Gonzalo Alonso-Salinas19Pablo Díez-Villanueva20Cardiology Service, Hospital Universitario Severo Ochoa, Madrid, SpainFaculty of Health Sciences, Alfonso X El Sabio University, Madrid, SpainCardiology Service, Hospital Universitario Virgen Macarena, Sevilla, SpainCardiology Service, Hospital Universitari I Politécnic La Fe, Valencia, SpainCentro de Investigación Biomedica en Red Cardiovascular (CIBERCV), Madrid, SpainCardiology Service, Hospital Universitario de Torrevieja, Alicante, SpainCardiology Service, Hospital de Palamós, Gerona, SpainCentro de Investigación Biomedica en Red Cardiovascular (CIBERCV), Madrid, SpainCardiology Service, Hospital Clínico Universitario de Santiago de Compostela, La Coruña, SpainCentro de Investigación Biomedica en Red Cardiovascular (CIBERCV), Madrid, SpainCardiology Service, Hospital Clínico Universitario de Valencia, Valencia, Spain0Insitute of Health Research-INCLIVA, Valencia, Spain1Universidad de Valencia, Valencia, Spain2Cardiology Service, Hospital Universitario de Toledo, Toledo, Spain3Cardiology Service, Hospital Universitario Reina Sofía, Córdoba, Spain4Cardiology Service, Hospital Universitario LaPaz, Madrid, Spain5Cardiology Service, Hospital Universitario Dr. Trueta, Gerona, Spain6Cardiology Service, Hospital Clínico Universitario Virgen de la Arixaca, Murcia, Spain7Cardiology Service, Hospital del Mar, Barcelona, Spain8Cardiology Service, Hospital Universitario de Navarra, Pamplona, Spain9Cardiology Service, Hospital Universitario de La Princesa, Madrid, SpainIntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.Material and methodsThis cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) years. Patients in VERISEC were older and had more comorbidities (diabetes, advanced chronic kidney disease) compared to VICTORIA, with 20% having an estimated glomerular filtration rate below 30 ml/min. They also had higher natriuretic peptide levels [NT-proBNP: 3551 (IQR: 1,675.9, 7,054.0)] pg/ml. Most patients (79.8%) started vericiguat after HF decompensation within the previous three months, with high use of loop diuretics (with an average dose of 65 mg/day) and implanted devices (50%). Sixty percent of patients were on quadruple therapy, with a higher use of sodium-glucose co-transporter 2 inhibitors compared to the VICTORIA trial. Despite the more severe disease in the VERISEC cohort, the implementation of guideline-directed medical therapy was greater than in VICTORIA, although vericiguat was initiated at lower blood pressure levels.ConclusionsPatients in the VERISEC registry had more severe illness and higher comorbidities compared to those in the VICTORIA, despite receiving optimised treatments. Further research is needed to identify which patients may benefit the most from vericiguat treatment.https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/fullvericiguatworsening heart failureguideline-directed medical therapyVERISEC registryheart failure reduced ejection fraction |
| spellingShingle | Alberto Esteban-Fernández Alberto Esteban-Fernández Alejandro Recio-Mayoral Raquel López-Vilella Raquel López-Vilella Gregorio de Lara Moisés Barrantes-Castillo Inés Gómez-Otero Inés Gómez-Otero Julio Nuñez-Villota Julio Nuñez-Villota Julio Nuñez-Villota Julio Nuñez-Villota Carolina Robles-Gamboa José López-Aguilera Ángel Iniesta-Manjavacas Paula Fluviá Francisco Pastor-Pérez Laia Belarte-Tornero Gonzalo Alonso-Salinas Pablo Díez-Villanueva Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial Frontiers in Cardiovascular Medicine vericiguat worsening heart failure guideline-directed medical therapy VERISEC registry heart failure reduced ejection fraction |
| title | Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial |
| title_full | Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial |
| title_fullStr | Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial |
| title_full_unstemmed | Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial |
| title_short | Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial |
| title_sort | clinical profile of an unselected population with heart failure treated with vericiguat in real life differences with the victoria trial |
| topic | vericiguat worsening heart failure guideline-directed medical therapy VERISEC registry heart failure reduced ejection fraction |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1504427/full |
| work_keys_str_mv | AT albertoestebanfernandez clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT albertoestebanfernandez clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT alejandroreciomayoral clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT raquellopezvilella clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT raquellopezvilella clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT gregoriodelara clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT moisesbarrantescastillo clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT inesgomezotero clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT inesgomezotero clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT julionunezvillota clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT julionunezvillota clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT julionunezvillota clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT julionunezvillota clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT carolinaroblesgamboa clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT joselopezaguilera clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT angeliniestamanjavacas clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT paulafluvia clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT franciscopastorperez clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT laiabelartetornero clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT gonzaloalonsosalinas clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial AT pablodiezvillanueva clinicalprofileofanunselectedpopulationwithheartfailuretreatedwithvericiguatinreallifedifferenceswiththevictoriatrial |